The reading desk.

29 research-peptide vendors have published 20 or more COAs through Kovera Labs. Ion Peptide leads at 105 records with zero flags. Two heavy publishers have concentrated quality issues. The full ranked table, deduped flag breakdown, and what to do with it as a buyer.

We mirrored every certificate Kovera Labs has published. 146 vendor-clients, 99.9% median purity, 0.8% explicit failure rate - plus three vendors whose results stand out for the wrong reasons.

GLP-1 receptor agonists cause weight loss that is between 25% and 40% lean mass by default. Resistance training and protein intake shift that ratio. Here's the trial data and the protocol levers that actually move it.

The same operation now runs under two domains. The legacy site is still live, the new domain inherits the old contact infrastructure, and the Trustpilot review base was seeded via a promo-code review program. Here's the buyer-relevant breakdown.

The 2024 and 2026 Pharmacy Compounding Advisory Committee votes didn't close any peptide vendor — they closed the legal compounded GLP-1 telehealth channel (Hims, Ro, Mochi, Henry, Eden). That closure is what pushed demand toward the research-peptide market.

The compounded semaglutide market that emerged during the 2022–2024 brand-product shortage is largely closed in 2026. Here's what the FDA shortage status, 503A PCAC restrictions, and telehealth provider pivots actually mean for buyers.

Short answer: yes. Janoshik is a real EU third-party lab - we audited 200 of its public reports to check purity, identity, and whether failures get published. Here's what held up.

43% of vendor-claimed purity figures failed independent retesting. The gap concentrates in three patterns you can avoid before clicking buy.

A timeline of FDA actions affecting the US research-peptide market from late 2024 through April 2026 — Warning Letters, criminal cases, and the 503A PCAC vote that reshaped what compounding pharmacies could legally produce.

Amino Asylum, Peptide Sciences, and Paradigm Peptides each ceased operations under different circumstances. The signals that preceded each shutdown were public, dated, and ignored.

We applied a 10-signal hostname-aliasing check to 32 research-peptide vendor domains. Multiple confirmed alias clusters surfaced, including a smoking-gun shared Google Tag Manager ID linking three "different" peptide brands to one operator.

We documented Particle Peptides selling Retatrutide as 'GLP-3' and Summit Biotech selling 8 different FDA-cited compounds under code names like 'R-10mg', 'T-30mg', 'Sema-1', and 'Cagri'. Here's the pattern, the evidence, and what buyers should do about it.

Some research-peptide brands aren't separate vendors — they're hostname aliases pointing at a shared backend. Here's how to detect the pattern in under sixty seconds, with a worked example from our own audit cohort.

When two 'different' peptide vendors cite the exact same Janoshik test URL for the same product batch, they're sourcing from the same upstream manufacturer. We documented this pattern between Summit Biotech and the Peptopia community-tracker batches — confirming Geneza Pharmaceuticals as the shared upstream.

Four structural drivers behind peptide-vendor alias clusters — payment-processor mortality, FDA enforcement, community detection lag, and upstream-supply-chain consolidation.

Five 503A telehealth compounders audited under the same rubric - Trillium, Fifty410, Hims, Henry Meds, Mochi Health. Mochi leads on prescriber transparency (board-certified obesity-medicine physicians). Fifty410 leads on regulatory cleanliness. The full cohort comparison, scored.

They're not really "versus" - the two compounds work through different receptors and synergize. CJC-1295 hits the GHRH receptor; ipamorelin hits the ghrelin receptor. The stack is research-protocol canon. Here's the actual breakdown plus the comparison framing most buyers want.

Two repurposed drugs studied for longevity, two different mechanisms, two different evidence bases. Rapamycin has the strongest cross-species lifespan-extension data in pharmacology. Metformin has 60+ years of human safety data and the active TAME trial. The honest comparison.

Both are synthetic GHRH analogs that stimulate endogenous growth hormone release. Tesamorelin is FDA-approved for HIV-associated lipodystrophy; sermorelin was approved for pediatric GH deficiency but withdrawn in 2008. Different half-lives, different research-protocol applications, different price points.

Tirzepatide produced ~47% greater mean weight loss than semaglutide in SURMOUNT-5, the first head-to-head obesity trial. Tirzepatide is dual GLP-1 / GIP, semaglutide is GLP-1-only. Both FDA-approved, both shifting the compounded-pharmacy market through 2026.

Tesamorelin is a synthetic GHRH analog that prompts the pituitary to release endogenous GH. HGH is the hormone itself. Here's what the literature says about both, why a growing community is switching from one to the other, and what to consider before you do.

Retatrutide showed ~24% mean body-weight reduction in TRIUMPH-4 versus tirzepatide's ~22.5% in SURMOUNT — a 1.5–2 point delta. Retatrutide hits three receptors (GLP-1, GIP, glucagon), tirzepatide two. May 2026: retatrutide is Phase 3, not FDA-approved; tirzepatide is FDA-approved with compounded availability closing.

A research read on the peptides currently studied for longevity outcomes - rapamycin, NAD+, MOTS-c, GHK-Cu, Klotho, epitalon, GHRH analogs, and the rest. Which have human evidence, which have only model-organism data, and what each actually does at the mechanism level.

KLOW is a four-component peptide stack growing fast in research-protocol discussion. Here's the literature read - what each compound does, what the mechanism overlap argues, and what's actually been studied as a combination.

Eli Lilly's Phase 3 retatrutide program reads out across the TRIUMPH-1 through TRIUMPH-5 trials. The headline figure — ~24% mean body-weight reduction at 48 weeks — beats tirzepatide's SURMOUNT ceiling by 2–4 points. Here's what the published Phase 3 data shows, what it doesn't, and the 2026 FDA submission timeline.

BPC-157 and TB-500 are the most-stacked combination in research-peptide protocols. The compounds work through different mechanisms — angiogenesis vs actin sequestration — which is why the combination is studied. Here's the literature read.

TRIUMPH Phase 3 dose-titration schedule — 2 mg start, 4-week steps up to 12 mg weekly maintenance — with full literature read of the maintenance doses and tolerability protocols from Eli Lilly's published retatrutide trials. Not human-use guidance; regulatory state in May 2026 is Phase 3, no FDA approval.

GI events (nausea ~50% at high dose, vomiting, diarrhea) plus a 1–3 bpm heart-rate signal attributed to glucagon-receptor activity — the literature read of side-effect frequencies from the published Phase 2 and TRIUMPH Phase 3 retatrutide trials, including the TRIUMPH-5 cardiovascular question still pending.

Bacteriostatic water tightened in 2025-2026 as compounded GLP-1 demand reshaped the diluent market. Here's the current vendor map, supply signals, and the alternatives that are research-protocol valid.

Cloudiness in a reconstituted peptide vial is one of the most common buyer panics. It's sometimes harmless aggregation, sometimes contamination, sometimes solvent-induced precipitation. Here's how to tell which one.

Step-by-step BAC water + syringe math for the three retatrutide vial sizes most vendors stock. Built around the TRIUMPH-4 dose titration. Research only, not human-use guidance.

Bacteriostatic water, syringe selection, dose math, storage. The reference we wish existed when we started — the mechanics of reconstituting lyophilized peptide vials from a research-protocol perspective.

How to verify a Janoshik COA against the public database in ninety seconds. The four-step check catches fabricated certificates, edited figures, and wrong-batch COAs.

Eight failure modes, ranked by how often they appear in public Janoshik data and how hard they are for a buyer to catch before ordering.

Live vendor pricing for retatrutide, COA verification steps, and the regulatory framing every buyer should read before ordering. Auto-refreshed daily from each vendor's catalog.